Ester-modified 99mTcO[SN(R)S/S] mixed ligand complexes: synthesis and preliminary evaluation.

Area of Science:

• Radiochemistry
• Nuclear Medicine
• Medicinal Chemistry

Background:

• Technetium-99m (99mTc) radiopharmaceuticals are crucial for diagnostic imaging.
• Developing stable and targeted 99mTc complexes is essential for effective medical applications.
• Esterase activity in vivo can affect the biodistribution and efficacy of radiotracers.

Purpose of the Study:

• To synthesize and characterize novel 99mTc-(SNS/S) complexes with varying ester functionalities.
• To evaluate the in vitro stability and in vivo tissue distribution of these new 99mTc complexes.
• To explore their potential as brain-targeting radiopharmaceuticals.

Main Methods:

• Synthesis of two novel 99mTc-(SNS/S) complexes (mono-ester 3 and diester 4) and their corresponding oxorhenium(V) analogues (1 and 2).
• In vitro enzymatic hydrolysis assays to assess complex stability.
• In vivo tissue distribution studies in mice to determine brain uptake and blood clearance.

Main Results:

• Complex 3 (mono-ester) demonstrated stability upon enzymatic hydrolysis, while complex 4 (diester) was rapidly converted to a hydrophilic metabolite.
• Both complexes 3 and 4 exhibited significant initial brain uptake.
• Fast blood clearance was observed for both complexes 3 and 4.

Conclusions:

• The esterification pattern significantly influences the in vitro stability of 99mTc-(SNS/S) complexes.
• Complex 3 shows promising characteristics for further development as a brain imaging agent due to its stability and initial brain uptake.
• Further investigation is warranted to identify the hydrophilic metabolite of complex 4 and to optimize 99mTc complexes for targeted delivery.